Trial: 202007143

Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis

Phase

II (Cancer Control)

Principal Investigator

Oh, Stephen

Disease Site

Other Hematopoietic

Learn more about this study at: clinicaltrials.gov